Last reviewed · How we verify
AERAS-402 3.0 x 10^10 vp
AERAS-402 3.0 x 10^10 vp is a Biologic drug developed by Aeras. It is currently in Phase 1 development.
At a glance
| Generic name | AERAS-402 3.0 x 10^10 vp |
|---|---|
| Sponsor | Aeras |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of AERAS-402 in Healthy Infants (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AERAS-402 3.0 x 10^10 vp CI brief — competitive landscape report
- AERAS-402 3.0 x 10^10 vp updates RSS · CI watch RSS
- Aeras portfolio CI
Frequently asked questions about AERAS-402 3.0 x 10^10 vp
What is AERAS-402 3.0 x 10^10 vp?
AERAS-402 3.0 x 10^10 vp is a Biologic drug developed by Aeras.
Who makes AERAS-402 3.0 x 10^10 vp?
AERAS-402 3.0 x 10^10 vp is developed by Aeras (see full Aeras pipeline at /company/aeras).
What development phase is AERAS-402 3.0 x 10^10 vp in?
AERAS-402 3.0 x 10^10 vp is in Phase 1.
Related
- Manufacturer: Aeras — full pipeline
- Compare: AERAS-402 3.0 x 10^10 vp vs similar drugs
- Pricing: AERAS-402 3.0 x 10^10 vp cost, discount & access